Sign In
Buy AZN
$176.43
+1.50 (+0.86%)
At Close: Jun 22, 2026
Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights
07:16pm, Thursday, 23'rd Apr 2026
Astrazeneca (AZN) concluded the recent trading session at $192.3, signifying a -1.29% move from its prior day's close.
AstraZeneca's Ultomiris Meets Goal in Rare Kidney Disease Study
12:21pm, Tuesday, 21'st Apr 2026
AZN's Ultomiris hits key goal in IgAN study, showing early proteinuria reduction as it eyes accelerated approval in major markets.
Germany risks missing out on new drugs, AstraZeneca CEO tells paper
08:50am, Tuesday, 21'st Apr 2026
AstraZeneca's CEO told daily Handelsblatt on Tuesday that Germany risks missing out on new drugs that the Anglo-Swedish drugmaker plans to launch if the nation sticks with plans to keep spending
AstraZeneca's tozorakimab treble puts $5bn sales ceiling in sight, says Citi
06:07am, Tuesday, 21'st Apr 2026
A third consecutive phase III success for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) tozorakimab in chronic obstructive pulmonary disease (COPD) has reinforced Citi's conviction in the drug's blockbuster p
AstraZeneca's Ultomiris hits primary endpoint in rare kidney disease trial
04:16am, Tuesday, 21'st Apr 2026
AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) Ultomiris has met its primary endpoint in a phase III trial targeting immunoglobulin A nephropathy (IgAN), a rare...
AstraZeneca's Ultomiris hits primary endpoint in rare kidney disease trial
03:18am, Tuesday, 21'st Apr 2026
AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) Ultomiris has met its primary endpoint in a phase III trial targeting immunoglobulin A nephropathy (IgAN), a rare inflammatory kidney disease that can progress
AstraZeneca's Ultomiris reduces urine protein in late-stage trial of rare kidney disease
02:26am, Tuesday, 21'st Apr 2026
AstraZeneca said on Tuesday its rare blood disorder drug Ultomiris met the main goal of a late stage trial, showing a reduction in protein found in the urine of
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
07:00am, Monday, 20'th Apr 2026
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinica
Farther Finance Advisors LLC Has $2.08 Million Position in Astrazeneca Plc $AZN
04:20am, Monday, 20'th Apr 2026
Farther Finance Advisors LLC increased its stake in shares of Astrazeneca Plc (NYSE: AZN) by 121.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exch
AstraZeneca's tozorakimab delivers sharp reduction in COPD flare‑ups
02:17am, Monday, 20'th Apr 2026
AstraZeneca said on Monday its experimental treatment tozorakimab met the main goal in a late-stage trial, reflecting a sharp reduction in moderate-to-severe flare-ups
Assetmark Inc. Buys 25,004 Shares of Astrazeneca Plc $AZN
03:24am, Thursday, 16'th Apr 2026
Assetmark Inc. raised its stake in Astrazeneca Plc (NYSE: AZN) by 8.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The in
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
07:16pm, Wednesday, 15'th Apr 2026
Astrazeneca (AZN) reached $201.21 at the closing of the latest trading day, reflecting a -1.55% change compared to its last close.
Bingham Private Wealth LLC Takes $669,000 Position in Astrazeneca Plc $AZN
03:31am, Wednesday, 15'th Apr 2026
Bingham Private Wealth LLC acquired a new stake in Astrazeneca Plc (NYSE: AZN) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Co
Are Medical Stocks Lagging AstraZeneca (AZN) This Year?
10:41am, Monday, 13'th Apr 2026
Here is how Astrazeneca (AZN) and ArriVent BioPharma, Inc. (AVBP) have performed compared to their sector so far this year.
Choreo LLC Purchases 3,362 Shares of Astrazeneca Plc $AZN
04:09am, Monday, 13'th Apr 2026
Choreo LLC increased its position in Astrazeneca Plc (NYSE: AZN) by 7.1% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 50,441 shares of the company's s
